Blood Advances
Monitoring detected blood cancers with less marrow scarring
The median share of JAK2 gene copies carrying a mutation was 13.0% at diagnosis in monitored cases versus 41.3% in referral-diagnosed cases.The median share of JAK2 gene copies carrying a mutation was 13.0% at diagnosis in monitored cases versus 41.3% in referral-diagnosed cases.
Cohort · 61 peopleInterventions
Who was studied61 JAK2 mutation carriers, against referral-diagnosed blood cancer cases
What changedNo marrow scarring was found in 80% of surveillance-detected cases versus 15% of referral-diagnosed cases
The catchReferral-diagnosed cases may have had faster-progressing disease than surveillance-detected cases